Processa Pharmaceuticals

Company snapshot

Processa Pharmaceuticals was founded in October 2017 with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The company is headquartered in Hanover, Maryland.

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Processa Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  CASI Pharmaceuticals

  TA overlap score 24.4

• Peer + 0 momentum

  Prime Medicine

  TA overlap score 23.4

• Peer + 0 momentum

  Zentalis Pharmaceuticals

  TA overlap score 22.8

Recent activity

Latest pipeline, patent, and corporate events for Processa Pharmaceuticals.

1. Jun 5, 2026 Clinical update

   PCS12852 — Phase 2

2. Jun 5, 2026 Clinical update

   HT-100 — Phase 2

3. May 23, 2026 Clinical update

   PCS499 — Phase 2

4. May 23, 2026 Clinical update

   PCS6422 and capecitabine — Phase 2

5. May 23, 2026 Clinical update

   RX-3117 — Phase 2

View all clinical trial activity →

• What is Processa Pharmaceuticals?

  Processa Pharmaceuticals is a pharma organization headquartered in Hanover, USA. It trades on NYSE under ticker PCSA. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Gastroparesis, Necrobiosis Lipoidica, Advanced Cancer, Breast Cancer. NovaPharmaNews links 8

• Is Processa Pharmaceuticals publicly traded?

  Yes. Processa Pharmaceuticals is listed with ticker PCSA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Processa Pharmaceuticals develop or market?

  We link 2 drug profile(s) where Processa Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/processa-pharmaceuticals#company-drugs.

• What are the latest developments for Processa Pharmaceuticals?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Processa Pharmaceuticals focus on?

  Processa Pharmaceuticals focuses on Duchenne Muscular Dystrophy, Gastroparesis, Necrobiosis Lipoidica based on our analysis of their pipeline programs and drug development activities.